SRPT is a high‑margin, cash‑rich rare‑disease gene‑therapy specialist whose approved DMD franchise and advancing Phase 3 program are attracting passive institutional buying despite a short cash runway and an operational‑risk heavy profile.
| Metric | SRPT |
|---|---|
| Revenue (latest Q) | $731M |
| Revenue YoY | -1.9% |
| Operating margin | 49.0% |
| Net income | $331M |
| Net margin | 45.3% |
| Free cash flow | $-205M |
| Cash | $653M |
| Total debt | $838M |
| Market cap | $2.10B |
| P/E (TTM) | N/M |
Over the trailing 90‑day window ending July 18 2026, Sarepta Therapeutics, Inc. (SRPT) recorded no discretionary open‑market purchases or sales by insiders. The Flow signal shows 0 buyers and 0 sellers, with a net discretionary value of $0 and a total of eight Form 4 filings that were all classified as planned 10b5‑1 transactions (which are excluded from the discretionary metric). Consequently, there are no notable insider buyers or sellers to highlight, and the data provides no directional signal about insider sentiment.
In the most recent quarter (ended 2026‑06‑30), the consensus of the ~760 notable funds that track SRPT shows a clear accumulation signal. Four notable holders entered the stock this quarter, contributing a net purchase of $4.26 million. There were no exits, no reductions, and no existing holders that trimmed their positions.
All of the notable owners are passive 13G filers, indicating no activist campaigns targeting SRPT at this time. The largest passive stakes are held by:
No 13D filings (activist positions) were returned for SRPT, and the available forced‑seller watchlist does not highlight any advisers shedding SRPT exposure, so there is no evidence of redemption‑driven selling pressure on the stock.
Sarepta Therapeutics’ 2025 Form 10‑K provides a clear view of how the company frames its clinical‑trial activities. The filing first offers a formal definition of a “Clinical Trial,” encompassing all phases from early‑stage investigations through post‑approval studies:
“1.86 “Clinical Trial” means any clinical investigation in which a pharmaceutical product is administered or dispensed to, or used involving human subjects, including any Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, or any post‑approval clinical trial in humans.”
The company then references the specific protocols governing its ongoing studies, indicating that the current study protocols are attached as an exhibit:
“Clinical Trial, the study protocol existing as of the Execution Date, attached hereto as Schedule 1.144 (Existing Clinical Trials Protocols).”
Regarding its lead product ELEVIDYS, Sarepta emphasizes that the trials are not only advancing development but also satisfying FDA post‑marketing commitments:
“We are conducting various clinical trials for ELEVIDYS, including studies that are required to comply with our post‑marketing FDA requirements and commitments to verify and describe clinical benefit.”
The filing also highlights the regulatory‑submission component of its trial program:
“2.1(a) (Clinical Trial Regulatory Submissions).”
Finally, Sarepta underscores the scale and purpose of its Phase 3 work, noting that larger trials are designed to confirm efficacy, dosage, and safety across a geographically dispersed patient population:
“* Phase 3. Larger Phase 3 clinical trials are conducted to confirm clinical efficacy, dosage and safety in the intended patient population, which may involve geographically dispersed clinical trial sites.”
Collectively, these excerpts show that Sarepta’s filings focus heavily on defining trial scope, linking studies to regulatory obligations, and stressing the breadth of its Phase 3 programs as a cornerstone of its product‑development strategy.
Sarepta Therapeutics (SRPT) places a markedly higher emphasis on Business & Operational risks (≈ 50.6 % of Item 1A text) than its peers – CRISPR Therapeutics (≈ 30.6 %) and Editas Medicine (no explicit label, but well below SRPT’s share). This focus reflects extensive discussion of manufacturing, supply‑chain and commercialization challenges.
Conversely, SRPT under‑weights Intellectual Property risk (≈ 6.7 %) relative to CRISPR (≈ 30.5 %) and Editas (≈ 18 %). The company also devotes less space to Legal & Regulatory risk (absent as a primary label) compared with Editas, where such risks account for roughly one‑third of its disclosure.
Among the multi‑label topics, SRPT’s Item 1A is dominated by Supplier Concentration (≈ 31 % of topic characters) and Stock‑Price Volatility (≈ 23 %). Neither CRISPR nor Editas surface these topics, and Editas’s IP‑protection discussion consumes over 60 % of its topic share, dwarfing SRPT’s 15 %.
General Risks – Unfavorable and uncertain global economic conditions could harm our business, financial condition or results of operations.
Overall, the dimensions that most differentiate Sarepta are its heavy weighting of operational and supply‑chain risk and its comparatively modest emphasis on IP‑related and regulatory risk.
According to the most recent pipeline snapshot (2026‑03‑02) Sarepta Therapeutics, Inc. (ticker SRPT) lists 14 assets spanning gene‑therapy and RNA‑oligo modalities.
Summary of development status (pipeline snapshot):
De‑risking score (as of 2026‑07‑18) is 0.7431 on a 0‑1 scale. The composite reflects:
“Score 0.7431 – a higher number indicates a more de‑risked profile with smaller expected absolute moves.” – bio_risk_score output
FDA approval history (original submissions only, since 2015):
Lead‑program target risk signal: the lead product ELEVIDYS targets the dystrophin gene (DMD). A query of historical phase‑advancement rates for DMD returned “insufficient priors,” indicating that the database does not contain enough resolved programs on this target to compute a meaningful success rate.